Synergistic apoptosis induction in leukemic cells by miR-15a/16-1 and arsenic trioxide

Biochemical and Biophysical Research Communications

Volumn 403, Issue 2, 2010, Pages 203-208

  Gao, Shen meng ^a   Chen, Chiqi ^a   Wu, Jianbo ^a   Tan, Yanxia ^a   Yu, Kang ^a,b   Xing, Chong Yun ^a   Ye, Aifang ^a   Yin, Lihui ^a   Jiang, Lei ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^b WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Arsenic trioxide; Leukemia; MiR 15a 16 1

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; CASPASE 3; CYTOCHROME C; MICRORNA; MICRORNA 15A; MICRORNA 16 1; POLY(ADENOSINE DIPHOSPHATE RIBOSE); UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CELL STRAIN K 562; DRUG EFFECT; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME DEGRADATION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; ARSENICALS; DRUG SYNERGISM; FUSION PROTEINS, BCR-ABL; HUMANS; K562 CELLS; LEUKEMIA, PROMYELOCYTIC, ACUTE; MICRORNAS; MITOCHONDRIA; OXIDES;

EID: 78649905889     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2010.10.137     Document Type: Article

References (33)

1. Liu Z., Sall A., Yang D. MicroRNA: an emerging therapeutic target and intervention tool. Int. J. Mol. Sci. 2008, 9:978-999.
2. Friedman J.M., Liang G., Liu C.C., Wolff E.M., Tsai Y.C., Ye W., Zhou X., Jones P.A. The putative tumor suppressor microRNA-101 modulates the cancer epigenome by repressing the polycomb group protein EZH2. Cancer Res. 2009, 69:2623-2629.
3. Ventura A., Jacks T. MicroRNAs and cancer: short RNAs go a long way. Cell 2009, 136:586-591.
4. Calin G.A., Dumitru C.D., Shimizu M., Bichi R., Zupo S., Noch E., Aldler H., Rattan S., Keating M., Rai K., Rassenti L., Kipps T., Negrini M., Bullrich F., Croce C.M. Frequent deletions and down-regulation of micro-RNA genes miR15and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. 2002, 99:15524-15529.
5. Salerno E., Scaglione B.J., Coffman F.D., Brown B.D., Baccarini A., Fernandes H., Marti G., Raveche E.S. Correcting miR-15a/16 genetic defect in New Zealand Black mouse model of CLL enhances drug sensitivity. Mol. Cancer Ther. 2009, 8:2684-2692.
6. Xia L., Zhang D., Du R., Pan Y., Zhao L., Sun S., Hong L., Liu J., Fan D. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. Int. J. Cancer 2008, 123:372-379.
7. Cimmino A., Calin G.A., Fabbri M., Iorio M.V., Ferracin M., Shimizu M., Wojcik S.E., Aqeilan R.I., Zupo S., Dono M., Rassenti L., Alder H., Volinia S., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Natl. Acad. Sci. USA 2005, 102:13944-13949.
8. Bonci D., Coppola V., Musumeci M., Addario A., Giuffrida R., Memeo L., D'Urso L., Pagliuca A., Biffoni M., Labbaye C., Bartucci M., Muto G., Peschle C., De Maria R. The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat. Med. 2008, 14:1271-1277.
9. Aqeilan R.I., Calin G.A., Croce C.M. MiR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ 2010, 17:215-220.
10. Soignet S.L., Maslak P., Wang Z.G., Jhanwar S., Calleja E., Dardashti L.J., Corso D., DeBlasio A., Gabrilove J., Scheinberg D.A., Pandolfi P.P., Warrell R.P. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998, 339:1341-1348.
11. Chen G.Q., Zhu J., Shi X.G., Ni J.H., Zhong H.J., Si G.Y., Jin X.L., Tang W., Li X.S., Xong S.M., Shen Z.X., Sun G.L., Ma J., Zhang P., Zhang T.D., Gazin C., Naoe T., Chen S.J., Wang Z.Y., Chen Z. In vitro studies on cellular and molecular mechanisms of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: As2O3 induces NB4 cell apoptosis with downregulation of Bcl-2 expression and modulation of PML-RAR alpha/PML proteins. Blood. 1996, 88:1052-1061.
12. Goering P.L., Aposhian H.V., Mass M.J., Cebrian M., Beck B.D., Waalkes M.P. The enigma of arsenic carcinogenesis: role of metabolism. Toxicol. Sci. 1999, 49:5-14.
13. Li Y., Zhu X., Gu J., Dong D., Yao J., Lin C., Huang K., Fei J. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis. Cancer Sci. 2010, 101:948-954.
14. Zhang Q.Y., Mao J.H., Liu P., Huang Q.H., Lu J., Xie Y.Y., Weng L., Zhang Y., Chen Q., Chen S.J., Chen Z. A systems biology understanding of the synergistic effects of arsenic sulfide and Imatinib in BCR/ABL-associated leukemia. Proc. Natl. Acad. Sci. USA 2009, 106:3378-3383.
15. Yin T., Wu Y.L., Sun H.P., Sun G.L., Du Y.Z., Wang K.K., Zhang J., Chen G.Q., Chen S.J., Chen Z. Combined effects of As4S4 and Imatinib on chronic myeloid leukemia cells and BCR-ABL oncoprotein. Blood 2004, 104:4219-4225.
16. Hochhaus A., Berger U., Reiter A., Engelich G., Lahaye T., Kreil S., Merx K., Muller M.C., Hehlmann R. Current therapy concepts in chronic myeloid leukemia. Study IV of the German CML Study Group. Internist (Berl) 2002, 43:1228. 1231-8, 1241-4.
17. Calabretta B., Perrotti D. The biology of CML blast crisis. Blood 2004, 103:4010-4022.
18. Duan X.F., Wu Y.L., Xu H.Z., Zhao M., Zhuang H.Y., Wang X.D., Yan H., Chen G.Q. Synergistic mitosis-arresting effects of arsenic trioxide and paclitaxel on human malignant lymphocytes. Chem. Biol. Interact. 2010, 183:222-230.
19. Gu J., Zhu X., Li Y., Dong D., Yao J., Lin C., Huang K., Hu H., Fei J. MiRNA-21 regulates arsenic-induced anti-leukemia activity in myelogenous cell lines. Med. Oncol. 2010, 10.1007/s12032-009-9413-7.
20. Calin G.A., Cimmino A., Fabbri M., Ferracin M., Wojcik S.E., Shimizu M., Taccioli C., Zanesi N., Garzon R., Aqeilan R.I., Alder H., Volinia S., Rassenti L., Liu X., Liu C.G., Kipps T.J., Negrini M., Croce C.M. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc. Natl. Acad. Sci. USA 2008, 105:5166-5171.
21. Man-Gen Song S.-M.G. Ke-Ming Du Nanomolar concentration of NSC606985, a camptothecin analog, induces leukemic-cell apoptosis through protein kinase C-dependent mechanisms. Blood 2005, 105:3714-3721.
22. Gabert J., Beillard E., van der Velden V.H., Bi W., Grimwade D., Pallisgaard N., Barbany G., Cazzaniga G., Cayuela J.M., Cave H., Pane F., Aerts J.L., De Micheli D., Thirion X., Pradel V., Gonzalez M., Viehmann S., Malec M., Saglio G., van Dongen J.J. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia - a Europe Against Cancer program. Leukemia 2003, 17:2318-2357.
23. Jiang L., Chen Y., Chan C.Y., Wang X., Lin L., He M.L., Lin M.C., Yew D.T., Sung J.J., Li J.C., Kung H.F. Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett. 2009, 274:101-108.
24. Perkins C., Kim C.N., Fang G., Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000, 95:1014-1022.
25. Lim L.P., Lau N.C., Garrett-Engele P., Grimson A., Schelter J.M., Castle J., Bartel D.P., Linsley P.S., Johnson J.M. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature 2005, 433:769-773.
26. Hagan J.P., Croce C.M. MicroRNAs in carcinogenesis. Cytogenet. Genome Res. 2007, 118:252-259.
27. Blower P.E., Chung J.H., Verducci J.S., Lin S., Park J.K., Dai Z., Liu C.G., Schmittgen T.D., Reinhold W.C., Croce C.M., Weinstein J.N., Sadee W. MicroRNAs modulate the chemosensitivity of tumor cells. Mol. Cancer Ther. 2008, 7:1-9.
28. Chen R.W., Bemis L.T., Amato C.M., Myint H., Tran H., Birks D.K., Eckhardt S.G., Robinson W.A. Truncation in CCND1 mRNA alters miR-16-1 regulation in mantle cell lymphoma. Blood 2008, 112:822-829.
29. Garzon R., Pichiorri F., Palumbo T., Visentini M., Aqeilan R., Cimmino A., Wang H., Sun H., Volinia S., Alder H., Calin G.A., Liu C.G., Andreeff M., Croce C.M. MicroRNA gene expression during retinoic acid-induced differentiation of human acute promyelocytic leukemia. Oncogene 2007, 26:4148-4157.
30. Lawrie C.H. MicroRNAs and haematology: small molecules, big function. Br. J. Haematol. 2007, 137:503-512.
31. 3 enhances selective cytotoxic effects of STI-571 against Brc-Abl-positive acute leukemia cells. Leukemia 2001, 15:772-778.
32. Skorski T. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability. Oncogene 2002, 21:8591-8604.
33. Wang J.Y. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000, 19:5643-5650.